Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma.

@article{Campbell2003OptimumTL,
  title={Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma.},
  author={Janine Campbell and Jane Matthews and John F Seymour and Max M Wolf and Surender K Juneja},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2003},
  volume={14 2},
  pages={273-6}
}
BACKGROUND The National Cancer Institute has recommended a bone marrow biopsy length of >/=20 mm for the staging and surveillance of patients with non-Hodgkin's lymphoma. However, there are few published data to support this recommendation, particularly the role of examining multiple levels. PATIENTS AND METHODS Bone marrow biopsies from 172 patients with newly diagnosed diffuse large cell lymphoma (DLCL) entered in two consecutive trials of the Australasian Leukaemia and Lymphoma Group were… CONTINUE READING
18 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Dose-intensification does not improve outcome in aggressive non-Hodgkin’s lymphoma (NHL). Report of a randomised trial by the Australasian Leukaemia and Lymphoma Group

  • M Wolf, J Matthews, J Stone
  • American Society of Hematology Annual Meeting,
  • 2000

Clinical and prognostic significance of bone marrow involvement in patients with diffuse large cell lymphoma

  • Y Yan, WC Chan, DD Weisenburger
  • J Clin Oncol
  • 1995

Similar Papers

Loading similar papers…